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OBJECTIVES: Health authorities are keen to understand the clin-
ical beneﬁts and mortality reduction afforded by HPV vaccina-
tion for cervical cancer. Complex decision models are not always
the most attractive nor the most appropriate means to highlight
these beneﬁts. The objective was to develop a relatively simple
model to explore the population level impact of an HPV16/18
vaccine. METHODS: We developed a Monte Carlo model that
estimated the absolute number of HPV infections, cervical cancer
cases and deaths over the lifetime of a cohort of women. The
model estimated the cancer cases and mortality avoided in 
the presence of vaccination (base-case: 75% vaccine uptake; 
95% lifetime efﬁcacy). RESULTS: Four countries were selected
including Germany, Poland, Mexico and Taiwan. Each country
has unique patterns of cervical cancer incidence, HPV-type 
prevalence and cervical cancer screening programs. The model
predicted 4584, 4642, 4162 and 37,935 cases of cervical cancer
over the lifetime of unvaccinated 10 year-old girls in each 
of Poland, Germany, Taiwan and Mexico, respectively. Vaccina-
tion resulted in a reduction of total cervical cancer cases 
and deaths of 2392 and 1042 respectively in Poland; 2423 and
857 in Germany; 2143 and 930 in Taiwan and 16,780 and 
8381 in Mexico. Sensitivity analyses showed the most critical
factors in maximizing the beneﬁts of vaccination include vaccine
uptake, efﬁcacy, and duration of the protection. CONCLU-
SIONS: Monte Carlo simulation modeling can be a very power-
ful tool in understanding the potential beneﬁts of vaccination
against HPV infection for reducing cervical cancer and speciﬁc
mortality.
PIN22
USE OF PHARMACOKINETIC-PHARMACODYNAMIC
MODELING WITH MONTE CARLO SIMULATION TO REDUCE
ANTIBIOTIC EXPENDITURES WITHOUT COMPROMISING
PREDICTED EFFICACY
Frei CR1, Lewis JS2, Burgess DS1
1University of Texas at Austin and University of Texas Health Science
Center at San Antonio, San Antonio,TX, USA, 2University of Texas at
Austin and University of Texas Health Science Center at San Antonio
and University Health System, San Antonio,TX, USA
OBJECTIVES: Cefepime (CPM) 2g q8h is FDA-approved for the
empiric treatment of patients with febrile neutropenia. Pharma-
cokinetic-pharmacodynamic (PK-PD) studies have demonstrated
that cephalosporin efﬁcacy is associated with the percent-time
that the free drug concentration exceeds the minimum inhibitory
concentration (free %T > MIC). This study compares the free
%T > MIC achieved by CPM 2g q8h to four alternative cefepime
regimens in an attempt to determine whether antibiotic 
expenditures can be reduced without compromising predicted
efﬁcacy. METHODS: MIC distributions for Enterobacteriaceae,
Pseudomonas aeruginosa, and Acinetobacter baumanii were
extracted from the 2002 Intensive Care Unit Surveillance System
database. A 10,000-subject Monte Carlo simulation was exe-
cuted for each species/regimen pair using published PK parame-
ters and these MIC distributions. Cefepime probabilities of target
attainment (PTA) were determined for PK-PD targets of ≥50, 60,
and 70%T > MIC. PTA for CPM 2g q8h was compared to the
PTA of four alternative regimens. RESULTS: Overall, the 2002
ISS database contained 3543 Enterobacteriaceae (percent sus-
ceptible, 95%), 1260 P. aeruginosa (53%), and 271 A. baumanii
(36%) isolates. All CPM regimens achieved a PTA similar to that
of CPM 2g q8h against Enterobacteriaceae suggesting an oppor-
tunity for cost minimization. In addition, CPM 1g q6h achieved
equivalent or higher PTA than CPM 2g q8h against P. aerugi-
nosa, and A. baumanii suggesting that the former regimen could
be used to achieve similar predicted efﬁcacy at a fraction of the
daily cost (4g/d vs. 6g/d). However, the PTA vs. P. aeruginosa
and A. baumanii was considerably lower for CPM 1g q8h, 1g
q12h, and 2g q12h compared to CPM 2g q8h suggesting that
these regimens may not be suitable alternatives for P. aeruginosa
or A. baumanii. CONCLUSION: PK-PD models with Monte
Carlo simulation demonstrate that cefepime 1g q6h results in
similar predicted efﬁcacy to cefepime 2g q8h despite a reduction
in total daily drug of 2g/d.
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OBJECTIVES: Many childhood vaccines not only protect those
directly immunized, but also indirectly prevent infection or
disease in the non-immunized population through herd effects.
Our objectives were to review the methodological approaches of
including indirect beneﬁts of herd effects in economic evaluations
of childhood vaccines and to describe the sensitivity of the cost-
effectiveness results to herd effects. METHODS: An extensive sys-
tematic review of the literature was conducted. The EMBASE,
MEDLINE, Biosis and Current Contents databases were reviewed
from 1995–2005. Two independent researchers reviewed titles
and abstracts of each article. Additional articles referenced in our
primary search were reviewed for further inclusion. Articles
meeting inclusion criteria were blinded. Two independent
researchers then reviewed and extracted data from all included
articles. The quality of each included article was assessed and any
discrepancies were resolved through consensus. RESULTS: Our
primary search resulted in 27 titles being identiﬁed. Four articles
met our inclusion criteria and 23 articles were excluded (7 review
papers, 7 non-economic, 7 did not include herd effects and 2 did
not assess a childhood vaccine). In each economic evaluation, sen-
sitivity analyses demonstrated that the models were highly sensi-
tive to variations in the estimates of herd effects. In reviewing
how herd effects were being captured, various key issues were
noted: 1) the source of herd effects and the generalizability from
one population to another; 2) the association between herd effects
and the vaccine; and 3) implications of a static or dynamic
approach to incorporate indirect beneﬁts. CONCLUSION: The
indirect beneﬁts attributed to herd effects have been documented
for several vaccines. Economic evaluations have been highly 
sensitive to variations in herd effects. Improving the precision of
measured outcomes at-tributed to herd effects in future economic
evaluations will advance research in this ﬁeld and assist in health
policy decision-making.
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